Spots Global Cancer Trial Database for prostate cancer metastatic
Every month we try and update this database with for prostate cancer metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | NCT03494803 | Prostate Cancer Prostate Adenoc... Prostate Cancer... | 18 Years - 90 Years | HKGepitherapeutics | ||
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | NCT06251492 | Prostate Cancer... Castration-resi... | Stereotactic bo... Adebrelimab | 18 Years - 75 Years | Fudan University | |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | NCT06136624 | Prostate Cancer... | Opevesostat Abiraterone ace... Enzalutamide Hydrocortisone Fludrocortisone... Prednisone Dexamethasone | - | Merck Sharp & Dohme LLC | |
| PROState Pathway Embedded Comparative Trial | NCT04400656 | Prostate Cancer Non-metastatic ... Metastatic Pros... Prostate Adenoc... Metastatic Pros... Prostate Cancer... | 18 Years - | Imperial College London | ||
| 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | NCT05570994 | Metastatic Cast... Prostate Cancer... Castrate Resist... | 177Lu HTK03170 68Ga-HTK03149 | 18 Years - | British Columbia Cancer Agency | |
| Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | NCT03396874 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostate Cancer... | 68Ga-PSMA | 18 Years - | University of Michigan | |
| Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303) | NCT03414437 | Prostate Cancer... | - | Carolina Research Professionals, LLC | ||
| Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics | NCT06260410 | Prostate Cancer... | Blood draw for ... | 18 Years - | Erasmus Medical Center | |
| Geriatric Assessment and Technology Evaluation in Prostate Cancer | NCT06215508 | Prostate Cancer Prostate Cancer... | Questionnaires | 18 Minutes - | University of Chicago | |
| Telaglenastat + Talazoparib In Prostate Cancer | NCT04824937 | Prostate Cancer... | Telaglenastat Talazoparib | 18 Years - | Massachusetts General Hospital | |
| Safety and Pharmacokinetics of ODM-209 | NCT03878823 | Prostate Cancer... Advanced Breast... Castration-resi... Metastatic Brea... | ODM-209 | 18 Years - | Orion Corporation, Orion Pharma | |
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | NCT02933801 | Prostate Cancer... Prostate Cancer | ODM-201 Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT01718353 | Prostate Cancer... | DOCETAXEL (XRP6... CABAZITAXEL (XR... Prednisone | 18 Years - | Sanofi | |
| Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone | NCT03988686 | Prostate Cancer... | Radical prostat... Standard of car... | 18 Years - 75 Years | Fudan University | |
| Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer | NCT03646162 | Prostate Cancer... | Veru-944 Placebo | 18 Years - | Veru Inc. | |
| A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT03575819 | Prostate Cancer... | FOR46 | 18 Years - | Fortis Therapeutics, Inc. | |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | NCT04335682 | Metastatic Pros... Prostate Cancer... Prostate Cancer Castrate Resist... | Darolutamide Enzalutamide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone | NCT01428219 | Prostate Cancer... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | NCT02074137 | Prostate Cancer... | CABAZITAXEL XRP... Prednisone Prednisolone | 18 Years - | Sanofi | |
| Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel | NCT02961257 | Prostate Cancer... | cabazitaxel Prednisone Granulocyte col... | 65 Years - | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | NCT02933801 | Prostate Cancer... Prostate Cancer | ODM-201 Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer | NCT04452136 | Prostatic Neopl... Prostatic Disea... Prostate Cancer Prostate Cancer... Prostate Cancer... | 68GA PSMA-HBED-... | 18 Years - | OHSU Knight Cancer Institute | |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors | NCT03129139 | Advanced Cancer Gastric Cancer Breast Cancer Pancreatic Canc... Prostate Cancer... Colo-rectal Can... Solid Tumor Solid Carcinoma Solid Carcinoma... Cancer of Stoma... | Minnelide™Capsu... | 18 Years - | Minneamrita Therapeutics LLC | |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | NCT04478279 | Glioblastoma Melanoma Stage ... Breast Cancer Prostate Cancer Glioblastoma Mu... GBM Brain Cancer Metastatic Brea... Metastatic Mela... Metastatic Pros... Melanoma Recurr... Prostate Cancer... Recurrent Gliob... Newly Diagnosed... | ST101 Temozolomide Radiation | 18 Years - | Sapience Therapeutics | |
| ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer | NCT05567770 | Prostate Cancer... | Actinium-J591 Stereotactic Bo... Androgen Depriv... | 18 Years - 90 Years | Weill Medical College of Cornell University | |
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | NCT05283330 | Cervical Cancer Prostate Cancer... Breast Cancer Colon Cancer NSCLC Cutaneous Melan... | ²¹²Pb-DOTAM-GRP... | 18 Years - | Orano Med LLC | |
| Geriatric Assessment and Technology Evaluation in Prostate Cancer | NCT06215508 | Prostate Cancer Prostate Cancer... | Questionnaires | 18 Minutes - | University of Chicago | |
| Ga-68-PSMA-11 in High-risk Prostate Cancer | NCT03362359 | High-risk Prost... Prostate Cancer Prostate Cancer... Lymphnode Metas... | Ga-68-PSMA-11 | 18 Years - | German Cancer Research Center | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) | NCT04833517 | Prostate Cancer... Castration Resi... Advanced Prosta... | 18 Years - | Universität des Saarlandes | ||
| A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC | NCT02378870 | Prostate Cancer... | Osteodex Placebo | 18 Years - | DexTech Medical AB | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis | NCT05627778 | Prostate Cancer... | 68Ga-PSMA-11 68Ga-P15-041 | 18 Years - 90 Years | Peking Union Medical College Hospital | |
| Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent | NCT02485691 | Prostate Cancer... | cabazitaxel XRP... enzalutamide abiraterone ace... prednisone | 18 Years - | Sanofi | |
| Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer | NCT03024216 | Prostate Cancer... | Atezolizumab120... Sipuleucel-T | 18 Years - | University of Hawaii | |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
| Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | NCT03396874 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostate Cancer... | 68Ga-PSMA | 18 Years - | University of Michigan | |
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | NCT06251492 | Prostate Cancer... Castration-resi... | Stereotactic bo... Adebrelimab | 18 Years - 75 Years | Fudan University | |
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | NCT02933801 | Prostate Cancer... Prostate Cancer | ODM-201 Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) | NCT05563558 | Prostate Cancer... | Pembrolizumab Carboplatin Cabazitaxel | 18 Years - | Fundacion Oncosur | |
| Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | NCT04116775 | Prostate Cancer Prostate Cancer... | Fecal microbiot... Pembrolizumab Enzalutamide | 18 Years - | Portland VA Medical Center | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer | NCT03024216 | Prostate Cancer... | Atezolizumab120... Sipuleucel-T | 18 Years - | University of Hawaii | |
| Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer | NCT04452136 | Prostatic Neopl... Prostatic Disea... Prostate Cancer Prostate Cancer... Prostate Cancer... | 68GA PSMA-HBED-... | 18 Years - | OHSU Knight Cancer Institute | |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases | NCT03569241 | Prostate Cancer Prostate Cancer... Metastatic Canc... Oligometastatic... | whole pelvic ra... metastasis-dire... salvage Lymph N... androgen depriv... | 18 Years - | University Hospital, Ghent | |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases | NCT03569241 | Prostate Cancer Prostate Cancer... Metastatic Canc... Oligometastatic... | whole pelvic ra... metastasis-dire... salvage Lymph N... androgen depriv... | 18 Years - | University Hospital, Ghent | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum | NCT05384002 | Prostate Cancer Prostate Cancer... Prostate Cancer... Prostate Cancer... | Magnetic Resona... | 18 Years - 85 Years | Fondazione del Piemonte per l'Oncologia | |
| Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate) | NCT05457699 | Prostate Cancer... | SABR no RT | - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT04781374 | Metastatic Pros... Castration-resi... Prostate Cancer Prostate Cancer... | Neratinib | 18 Years - | Beth Israel Deaconess Medical Center | |
| National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients | NCT04086290 | Prostate Cancer... | RARP SBRT ADT | 18 Years - | Herlev Hospital | |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients | NCT05156372 | Prostate Cancer... Castrate Resist... Metastatic Pros... Metastatic Pros... | High Intensity ... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide | NCT02379390 | Prostate Cancer... | Cabazitaxel XRP... Ezalutamide Abiraterone ace... Prednisone | 18 Years - | Sanofi | |
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | NCT04916613 | Prostate Cancer... | Darolutamide 30... Placebo Androgen depriv... | 18 Years - | UNICANCER | |
| Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | NCT04848337 | Prostate Cancer... Neuroendocrine ... | Pembrolizumab Lenvatinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | NCT04019327 | Prostate Cancer Prostate Adenoc... Prostate Neopla... Prostate Cancer... Castration-resi... | Talazoparib Temozolomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | NCT05067140 | Prostate Cancer... | ARV-766 Part A&... ARV-766 + Abira... | 18 Years - | Arvinas Inc. | |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors | NCT03129139 | Advanced Cancer Gastric Cancer Breast Cancer Pancreatic Canc... Prostate Cancer... Colo-rectal Can... Solid Tumor Solid Carcinoma Solid Carcinoma... Cancer of Stoma... | Minnelide™Capsu... | 18 Years - | Minneamrita Therapeutics LLC | |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) | NCT03434158 | Prostate Cancer... | Olaparib | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer | NCT03646162 | Prostate Cancer... | Veru-944 Placebo | 18 Years - | Veru Inc. | |
| Selective Treatment According to Molecular Subtype of Prostate Cancer | NCT03696186 | Castration-resi... Prostate Cancer... | Luminal type-1 Luminal type-2 Neuroendocrine ... Neuroendocrine ... Atypical type-1 Atypical type-2 | 18 Years - | Tianjin Medical University Second Hospital | |
| 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | NCT05570994 | Metastatic Cast... Prostate Cancer... Castrate Resist... | 177Lu HTK03170 68Ga-HTK03149 | 18 Years - | British Columbia Cancer Agency | |
| Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC | NCT02913196 | Prostate Cancer... | Apalutamide Abiraterone ace... Docetaxel Prednisone | 18 Years - | Weill Medical College of Cornell University | |
| Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | NCT01254279 | Prostate Cancer... | CABAZITAXEL | 18 Years - | Sanofi | |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer | NCT04641078 | Prostate Cancer Prostate Cancer... Prostate Cancer... Metastatic Canc... Oligometastasis | Darolutamide metastasis-dire... | 18 Years - | University Hospital, Ghent | |
| Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer | NCT03833921 | Prostate Cancer... Prostate Cancer | Abiraterone Ace... Prednisone | 18 Years - | Baylor College of Medicine | |
| BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC | NCT05530395 | Prostate Cancer... | Testosterone le... | 18 Years - 89 Years | University Hospital Virgen de las Nieves | |
| Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223 | NCT03223727 | Prostate Cancer... Bone Metastases | Blood tests | 18 Years - | The Netherlands Cancer Institute | |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | NCT03951831 | Prostate Cancer... | REGN2810 Degarelix Leuprolide Acet... Docetaxel | 18 Years - 99 Years | Columbia University | |
| National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients | NCT04086290 | Prostate Cancer... | RARP SBRT ADT | 18 Years - | Herlev Hospital | |
| Molecular Profiling in Prostate Cancer | NCT04983628 | Prostate Cancer... Prostate Cancer... Germline BRCA1 ... Germline BRCA2 ... Mutation | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | NCT02074137 | Prostate Cancer... | CABAZITAXEL XRP... Prednisone Prednisolone | 18 Years - | Sanofi | |
| Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | NCT03295565 | Prostate Cancer... Metastasis | Cabazitaxel Abiraterone Enzalutamide | 18 Years - | The Netherlands Cancer Institute | |
| BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC | NCT05530395 | Prostate Cancer... | Testosterone le... | 18 Years - 89 Years | University Hospital Virgen de las Nieves | |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) | NCT03434158 | Prostate Cancer... | Olaparib | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors | NCT03129139 | Advanced Cancer Gastric Cancer Breast Cancer Pancreatic Canc... Prostate Cancer... Colo-rectal Can... Solid Tumor Solid Carcinoma Solid Carcinoma... Cancer of Stoma... | Minnelide™Capsu... | 18 Years - | Minneamrita Therapeutics LLC | |
| Selective Treatment According to Molecular Subtype of Prostate Cancer | NCT03696186 | Castration-resi... Prostate Cancer... | Luminal type-1 Luminal type-2 Neuroendocrine ... Neuroendocrine ... Atypical type-1 Atypical type-2 | 18 Years - | Tianjin Medical University Second Hospital | |
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | NCT05361915 | Prostate Cancer Prostate Cancer... | Abivertinib Abiraterone | 18 Years - | Sorrento Therapeutics, Inc. | |
| Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer | NCT03888612 | Prostate Cancer... | ARV-110 | 18 Years - | Arvinas Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
